PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Gilead grabs its first approval for twice-yearly HIV therapy

The European Commission has become the first regulator worldwide to approve Gilead Sciences’ Sunlenca (lenacapavir) — the only twice-yearly add-on drug for people living with multidrug-resistant HIV.

Sunlenca is a first-in-class capsid inhibitor with a multi-stage mechanism of action and has no known cross-resistance to other existing drug classes. The drug, used in combination with other antivirals, will offer a new treatment option in an area with critical unmet needs — people with HIV whose virus no longer effectively responds to their current therapy.

The U.S. FDA rejected Gilead’s NDA for Sunlenca back in March. In the complete response letter, the FDA said its decision to reject the candidate was due to CMC issues with the glass vials the drug was intended to be distributed. Specifically, the agency raised questions about vials made of borosilicate glass and their compatibility with lenacapavir solution.

But the FDA accepted Gilead’s resubmission last month and gave the drug a PDUFA action date of December 27, 2022.

Once launched, Sunlenca will compete with ViiV Healthcare’s Rukobia, approved in both the U.S. and Europe, which is taken twice daily by mouth.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026